LOGIN  |  REGISTER
Viking Therapeutics
Amneal Pharmaceuticals

Owens & Minor to Present at Upcoming Investor Conferences on December 2, 2025

December 02, 2025 | Last Trade: US$2.68 0.01 0.37

RICHMOND, Va. / Dec 02, 2025 / Business Wire / Owens & Minor, Inc. (NYSE: OMI) announced today that members of its management team are scheduled to participate in two upcoming investor conferences.

Citi 2025 Global Healthcare Conference

On Tuesday, December 2, 2025, Ed Pesicka, the Company’s President and Chief Executive Officer, and Will Parrish, the Company’s Vice President of Strategy, Corporate Development, & Investor Relations, are scheduled to participate in a fireside chat at 2:30 P.M. ET and host one-on-one investor meetings at the conference in Miami, Florida.

Please visit the “Events & Presentations” section of the “Investor Relations” page on the Owens & Minor website available at https://investors.owens-minor.com at least 10 minutes in advance to register for the live webcast of the discussion. A replay of the webcast can be accessed following the presentation at the link provided above.

Bank of America Leveraged Finance Conference

On Tuesday, December 2, 2025, Jon Leon, the Company’s Executive Vice President and Chief Financial Officer, and Alex Miller, the Company’s Vice President of Tax & Treasury, are scheduled to host one-on-one investor meetings at the conference in Boca Raton, Florida.

About Owens & Minor

Owens & Minor, Inc. (NYSE: OMI) is a Fortune 500 global healthcare solutions company providing essential products and services that support care from the hospital to the home. For over 100 years, Owens & Minor and its affiliated brands, Apria®, Byram® and HALYARD*, have helped to make each day better for the patients, providers, and communities we serve. Powered by more than 20,000 teammates worldwide, Owens & Minor delivers comfort and confidence behind the scenes so healthcare stays at the forefront. Owens & Minor exists because every day, everywhere, Life Takes Care™. For more information about Owens & Minor and our affiliated brands, visit owens-minor.com or follow us on LinkedIn and Instagram.

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page